Immuno oncology News and Research

RSS

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have started production of Immutep’s ImmuFact IMP321 (a LAG-3Ig fusion protein) at WuXi AppTec facilities in China. The product is being produced to European, U.S. and Chinese GMP standards.

8 Apr 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development.

7 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check - for more than two years, in some cases - in many patients with advanced melanoma, according to a new study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions.

4 Mar 2014

LUNGevity Foundation awarded grant to develop educational materials on immuno-oncology

LUNGevity Foundation is honored to announce a grant of $250,000 from Bristol-Myers Squibb for the development of educational materials on immuno-oncology. Progress in understanding lung cancer and treatment approaches has accelerated dramatically in the past several years after many slow decades.

4 Mar 2014

Novartis acquires CoStim Pharmaceuticals

MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

17 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

17 Oct 2013

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have entered into an agreement regarding the development, commercialization and manufacturing of Immutep’s ImmuFact IMP321.

7 Oct 2013

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

...

27 Sep 2013

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

Today, Bristol-Myers Squibb is pleased to welcome the decision by The National Institute for Health and Clinical Excellence (NICE) to recommend Yervoy (ipilimumab) for the treatment of previously-treated advanced (unresectable or metastatic) melanoma within the Final Appraisal Determination (FAD).

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).

4 Jun 2012

Bristol-Myers Squibb forms International Immuno-Oncology Network

Bristol-Myers Squibb Company today announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the intelligence of the body's own immune system to fight cancer.

30 May 2012

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

31 Oct 2011

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

21 Sep 2011

EC approves YERVOY for treatment of previously-treated advanced melanoma

Bristol-Myers Squibb today announced that the European Commission has approved YERVOY for the treatment of adult patients with previously-treated advanced melanoma.

14 Jul 2011

Immuno oncology News and Research

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Drug that unleashes immune system can produce lasting remissions in patients with melanoma

LUNGevity Foundation awarded grant to develop educational materials on immuno-oncology

Novartis acquires CoStim Pharmaceuticals

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

Ablynx Nets Another $33.7M From Merck Serono As Partnership Expands

Bristol-Myers Squibb welcomes decision by NICE to recommend Yervoy for advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb forms International Immuno-Oncology Network

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

EC approves YERVOY for treatment of previously-treated advanced melanoma

Your guide to microplate readers for cancer research eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News